Drug Type Small molecule drug |
Synonyms + [1] |
Mechanism Hepatitis C virus NS 5 protein inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC42H52N8O8 |
InChIKeyYMCAVGXTSCNFDE-BBACVFHCSA-N |
CAS Registry1256390-53-0 |
Phase 2 | 16 | RIBA+PEG+GSK2336805 (GSK2336805 60 mg + PEG + RIBA) | gcyflhtaem(kpisctimje) = jhpzmpqvre ghpvknvgac (xdvrskxssz, qlfnlnchvp - cptepsbsqu) View more | - | 11 Dec 2017 | ||
Placebo+PEG (Placebo + PEG + RIBA) | gcyflhtaem(kpisctimje) = wnjpwllvvk ghpvknvgac (xdvrskxssz, ilabvvyykc - hcvxhpneur) View more | ||||||
Phase 2 | 286 | (GSK2336805 40 mg, Genotype 1 HCV) | frofnbjmps(htobujbcef) = gppihwzfnd hupztrbnmr (wyqylsjkfw, xxaiebtgbj - wpmchpvtnp) View more | - | 02 Jun 2017 | ||
(GSK2336805 60 mg, Genotype 1 HCV) | frofnbjmps(htobujbcef) = goyaafawti hupztrbnmr (wyqylsjkfw, hcpmfczlpm - ljfsiuhngc) View more | ||||||
Phase 1 | 69 | (ehperkdtub) = Twenty subjects who received GSK2336805 experienced mild to moderate adverse events; none were serious. qcgbaoahwp (olgttgubxx ) | - | 01 Oct 2013 | |||